Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about CAMP4 Therapeutics Corporation
CAMP4 Therapeutics Corporation News
May 16, 2025 - globenewswire.com
CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting
May 13, 2025 - globenewswire.com
CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights
Apr 28, 2025 - globenewswire.com
CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting
Mar 27, 2025 - globenewswire.com
CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update
CAMP4 Therapeutics Corporation Quantitative Score
About CAMP4 Therapeutics Corporation
CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.
CAMP4 Therapeutics Corporation Earnings & Revenue
CAMP4 Therapeutics Corporation Financials
Table Compare
Compare CAMP metrics with: | |||
|---|---|---|---|
Earnings & Growth | CAMP | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | CAMP | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | CAMP | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | CAMP | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
CAMP4 Therapeutics Corporation Income
CAMP4 Therapeutics Corporation Balance Sheet
CAMP4 Therapeutics Corporation Cash Flow
CAMP4 Therapeutics Corporation Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Buy |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
CAMP4 Therapeutics Corporation Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
CAMP4 Therapeutics Corporation Executives
| Name | Role |
|---|---|
| Mr. Joshua Mandel-Brehm | Chief Executive Officer, President & Director |
| Ms. Kelly Gold | Chief Financial Officer |
| Dr. Yuri Maricich M.B.A., M.D. | Chief Medical Officer |
| Dr. David Bumcrot Ph.D. | Chief Scientific Officer & Senior Vice President of Research |
| Dr. Richard A. Young Ph.D. | Founder & Independent Director |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Joshua Mandel-Brehm | Chief Executive Officer, President & Director | Male | 1983 | 1.89M |
| Ms. Kelly Gold | Chief Financial Officer | Female | 1978 | 905.53K |
| Dr. Yuri Maricich M.B.A., M.D. | Chief Medical Officer | 1981 | 822.43K | |
| Dr. David Bumcrot Ph.D. | Chief Scientific Officer & Senior Vice President of Research | 1963 | 501.93K | |
| Dr. Richard A. Young Ph.D. | Founder & Independent Director | 1954 | 143.05K |
CAMP4 Therapeutics Corporation Insider Trades
| Date | 17 Mar |
| Name | WILLIAMS DOUGLAS E |
| Role | Director |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 1 Apr |
| Name | Bumcrot David |
| Role | Chief Scientific Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 45000 |
| Date | 1 Apr |
| Name | Maricich Yuri |
| Role | Chief Medical Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 80000 |
| Date | 1 Apr |
| Name | Gold Kelly |
| Role | Chief Financial Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 80000 |
| Date | 1 Apr |
| Name | Mandel-Brehm Josh |
| Role | Chief Executive Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 160000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 17 Mar | WILLIAMS DOUGLAS E | Director | Disposed | 0 | |
| 1 Apr | Bumcrot David | Chief Scientific Officer | Acquired | A-Award | 45000 |
| 1 Apr | Maricich Yuri | Chief Medical Officer | Acquired | A-Award | 80000 |
| 1 Apr | Gold Kelly | Chief Financial Officer | Acquired | A-Award | 80000 |
| 1 Apr | Mandel-Brehm Josh | Chief Executive Officer | Acquired | A-Award | 160000 |